Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Indigenous Women's Experiences With Perinatal Nursing Care: Beyond Deficit Narratives to Work Toward Sovereign Wellbeing.

ANS. Advances in nursing science·2026
Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

The lancet. HIV·2026
Same author

Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB-IIIA non-small cell lung cancer.

Translational lung cancer research·2026
Same author

HER-2 Altered Early-Stage Non-Small Cell Lung Cancer Had Better Survival than Triple-Negative Disease.

Journal of clinical medicine·2026

相关实验视频

Updated: May 9, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

在osimertinib临床计划中进行EGFR突变测试.

Marie Laure Murat-Onana1, Suresh S Ramalingam2, Pasi A Jänne3

  • 1Precision Medicine & Biosamples, AstraZeneca, Cambridge, UK.

Lung cancer (Amsterdam, Netherlands)
|May 1, 2025
PubMed
概括
此摘要是机器生成的。

大多数组织样本足以用于非小细胞肺癌 (NSCLC) 的EGFR检测. 优化分析前变量和组织采样对于提高EGFR突变测试成功率至关重要.

关键词:
测试EGFR突变的测试.发生EGFR突变的原因非小细胞肺癌是非小细胞肺癌.奥西默蒂尼布 (Osimertinib) 是一种药物.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.8K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

相关实验视频

Last Updated: May 9, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.8K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

科学领域:

  • 在瘤学瘤学.
  • 分子诊断学 分子诊断
  • 癌症生物标志物 癌症生物标志物

背景情况:

  • 表皮生长因子受体 (EGFR) 突变是非小细胞肺癌 (NSCLC) 的关键驱动因素.
  • EGFR-氨酸激酶抑制剂 (TKI),如奥西默提尼布,已经改变了NSCLC的治疗方法.
  • 准确和早期识别EGFR突变对于有效的患者管理至关重要.

研究的目的:

  • 为了分析EGFR突变组织测试数据从临床试验的 osimertinib 在NSCLC.
  • 确定影响EGFR突变检测成功的挑战和因素.
  • 支持在NSCLC中对EGFR突变检测的最佳实践.

主要方法:

  • 从九个全球性 osimertinib NSCLC 临床试验中获得的Cobas® EGFR 突变测试数据的集中分析.
  • 基于样本类型,疾病阶段和地理区域的样本充分性和测试有效性的评估.
  • 分析测试不足的原因,包括瘤含量和组织体积不足.

主要成果:

  • 在4864次活检和2402次切除术中,91%的结果足以进行检测.
  • 活检显示12%的不足 (主要是瘤/组织不足),而切除则有3%的不足.
  • 检测不足因疾病阶段而异,在晚期/转移性环境和不可切除的III阶段更高.
  • 适当样本的测试成功率在93%至99%之间.

结论:

  • 大多数组织样本适合EGFR突变检测.
  • 组织或瘤含量不足是检测不足的主要原因,特别是在活检和晚期疾病阶段.
  • 优化预分析变量和组织采样技术对于提高NSCLCEGFR检测成功率至关重要.